Beta Drugs Reports Q2 Consolidated Net Profit of ₹19.3 Crore on Revenue of ₹137 Crore

Market snapshot: Beta Drugs Limited announced its Q2 consolidated financial performance, recording a net profit of ₹19.3 crore compared to ₹12 crore in the corresponding quarter of the previous year. Consolidated revenue reached ₹137 crore, expanding from ₹100 crore YoY. Operating performance was underscored by EBITDA of ₹30.3 crore and an EBITDA margin of 22.02%.

Data Snapshot

• Consolidated Net Profit stood at ₹19.3 crore in Q2, compared to ₹12 crore in Q2 of the prior fiscal year
• Consolidated Revenue rose to ₹137 crore in Q2 from ₹100 crore in the year-ago period
• EBITDA increased to ₹30.3 crore in Q2 from ₹21.3 crore in the corresponding prior-year quarter
• EBITDA Margin expanded to 22.02% in Q2 from 20.6% YoY

What's Changed

• Consolidated Net Profit increased ≈60.83% YoY (derived: ₹19.3 cr vs ₹12 cr)
• Consolidated Revenue expanded ≈37% YoY (derived: ₹137 cr vs ₹100 cr)
• EBITDA grew ≈42.25% YoY (derived: ₹30.3 cr vs ₹21.3 cr)
• EBITDA margin expanded by 142 bps YoY (derived: 22.02% vs 20.6%)

Key Takeaways

• Top-line expansion drove robust bottom-line profit growth for the quarter.
• Operating profitability strengthened with EBITDA margins expanding to 22.02%.
• Quarterly performance reflects sustained operational execution across active business segments.

SAHI Perspective

Beta Drugs demonstrated effective operational scaling during Q2. The combination of 37% revenue expansion and a 142 bps improvement in EBITDA margin indicates positive operating leverage and disciplined expense management across product formulations.

Market Implications

The quarterly earnings growth reinforces operational stability for Beta Drugs. Expansion in cash generation and operating profitability provides additional flexibility for ongoing corporate initiatives and capital allocation.

Trading Signals

Market Bias: Bullish

Positive earnings trajectory with consolidated net profit expanding to ₹19.3 crore (vs ₹12 crore YoY) and revenue reaching ₹137 crore supports a positive near-term bias.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Sustained quarterly revenue growth momentum
• Maintenance of EBITDA margins above 22%

Time Horizon: Near-term (0-3 months)

Industry Context

Indian pharmaceutical manufacturers focused on specialized oncology and critical care formulations continue to benefit from steady demand growth, encouraging investments in manufacturing efficiency and brand expansion.

Key Risks to Watch

• Potential volatility in active pharmaceutical ingredient input costs
• Ongoing compliance requirements across regulated manufacturing markets

Recent Developments

Beta Drugs reported Q1 consolidated sales of ₹125.55 crore with a net profit of ₹15.80 crore. The company scheduled its Q2 FY27 earnings conference call on October 22, 2026.

Closing Insight

Continued top-line expansion accompanied by operating margin improvement underscores Beta Drugs' sustained business momentum.

High Performance Trading with SAHI.